CLINICAL_TRIALS
trial_result
· 2021-08-13
Clinical Trial Update: Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG [Phase 3]
Summary
Phase 3 trial evaluating amifampridine phosphate in generalized myasthenia gravis (MuSK-MG) has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Myasthenia Gravis, Generalized | Phase 3 | Status: COMPLETED | Results posted: 2021-08-13